← boardnext 2029-02-28
BOLD
Boundless Bio, Inc.distress 2/10 · well-funded / low risk$2.53+0%today-3% from 52w high
Oncology 2
Lead: Breast Cancer · est. market ~$35B (approx, global)
Revenue
pre-revenue
Liquidity
$93M
Runway
2.0 yrs
Shares 1y
+0%
Price & events
+99.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.4%
1D
+1.6%
1W
-2.7%
1M
+66.4%
3M
+100.8%
6M
+104.0%
1Y
-29.7%
2Y
—
5Y
-82.2%
All
Overview
- Market Cap
- $56.83M
- Volume
- 24.43K
- 52 Week Range
- $1.05 – $2.60
- Total Shares
- 22.46M
- Float Shares
- 16.43M
- Short %
- 1.40%
- % Held by Insiders
- 11.35%
- % Held by Institutions
- 61.02%
- RVOL
- 0.01x
- Beta
- 0.40
Pipeline stages · 1 programs
BBI-940, Fulvestrant
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2029-02-28 Estimated 50% readout ~2029-03-30 | Phase 1 | BBI-940, Fulvestrant | Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer | — | recruiting |
| 2026-03-17 | Phase 1 | BBI-355, Erlotinib, Futibatinib | Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma, Anogenital Cancer, Head and Neck (HNSCC), Cutaneous Squamous Cell Carcinoma (CSCC), Cervical Squamous Cell Carcinoma, ER+ Breast Cancer, Leiomyosarcoma (LMS), Undifferentiated Pleomorphic Sarcoma (UPS), Pancreatic Cancer Metastatic, Small Cell Lung Cancer | 85 | terminated |
| 2025-06-25 | Phase 1 | BBI-825 | Solid Tumor | 19 | terminated |
Catalyst news & presentations · 7
- first half of 2026regulatory submissionFiled (NDA/BLA)BBI-940 · Expected submission of Investigational New Drug (IND) application.SEC 8-K
- first half of 2026regulatory submissionFiled (NDA/BLA)ecDTx 3 · IND application submissionSEC 8-K
- 2026-06-22partnershipEntered definitive merger agreement with Serapha Bio to combine operations.SEC 8-K
- 2025trial initiationsecondaryBBI-355/BBI-825 · Plans to initiate clinical development of the combination therapy.SEC 8-K
- second half of 2025readoutPhase 1/2BBI-355 · Initial clinical proof-of-concept dataSEC 8-K
- Tuesday, May 27conferencedata presentationsecondaryBBI-355/BBI-825 · Live webcast presenting scientific details on combination therapy.SEC 8-K
- 2025-05-23trial discontinuedBBI-355 · Discontinuing current arms of the POTENTIATE Phase 1/2 trial due to narrow therapeutic index and toxicity.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
hold · target $4 (+58% upside) · 1 analysts
- 2025-08-11HC Wainwright & Co.Buy
- 2025-06-02HC Wainwright & Co.Buy
- 2025-05-28Leerink PartnersOutperform → Market Perform
- 2024-12-13GuggenheimBuy → Neutral
Competitors — Breast Cancer
- NVSEFNOVARTIS AG$292.0B · D3
- GILDGILEAD SCIENCES, INC.$159.5B · D2
- PFEPFIZER INC$142.2B · D3
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- RLAYRelay Therapeutics, Inc.$3.6B · D6
- OLMAOlema Pharmaceuticals, Inc.$990M · D4
- PRLDPrelude Therapeutics Inc$307M · D6
- OKUROnKure Therapeutics, Inc.$172M · D6
- ATOSATOSSA THERAPEUTICS, INC.$22M · D6
- AZNASTRAZENECA PLC— · D3
Recent news
- 2026-07-22Form 4 Boundless Bio Inc For: 21 July By Investing.com - Investing.com South Africa
- 2026-07-22Boundless Bio director Kevin Tang buys $11,865 in shares By Investing.com - Investing.com Nigeria
- 2026-07-21Boundless Bio 10% owner Kevin Tang acquires $11,876 in common shares - Bitget
- 2026-07-21Boundless Bio (NASDAQ: BOLD) major Tang Capital holder adds 4,863 shares - Stock Titan
- 2026-07-19Boundless Bio Inc. (BOLD) Holds Near Support After Modest Decline - Buyback Factor - dars.gov.et
- 2026-07-17Tang Capital’s Kevin Tang reports $154,586 Boundless Bio common share purchase - Bitget
- 2026-07-17Boundless Bio: ten percent owner Kevin Tang buys $155,645 By Investing.com - Investing.com South Africa
- 2026-07-17Boundless Bio: ten percent owner Kevin Tang buys $155,645 - Investing.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.